Glucocorticoid-free induction regimen in severe ANCA-associated vasculitis using a combination of rituximab and eculizumab.
暂无分享,去创建一个
[1] D. Maucort-Boulch,et al. Mortality in systemic necrotizing vasculitides: A retrospective analysis of the French Vasculitis Study Group registry. , 2018, Autoimmunity reviews.
[2] M. Jadoul,et al. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. , 2017, Journal of the American Society of Nephrology : JASN.
[3] T. Schall,et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. , 2014, Journal of the American Society of Nephrology : JASN.
[4] P. Merkel,et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. , 2010, The New England journal of medicine.
[5] P. Heeringa,et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. , 2007, Kidney international.
[6] P. Heeringa,et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. , 2007, American Journal of Pathology.